Adarx Pharmaceuticals

US · ADRX #2823 by market cap Listed 2026

17.33 -1.25 -6.73%

Live - 5344 symbols - heartbeat 109s ago · 2026-10-08 08:27

Pre-market 17.67 +1.96%

After-hours 17.22 -0.63%

Overnight 17.04 -1.67%

Market cap: 1.77B
P/E (TTM): -20.15
P/B: -7.06
EPS: -0.97
Div yield: 0.00%
52W pos: 2%

Reader sentiment Are you bullish or bearish on ADRX?

Anonymous reader poll. Unscientific, not investment advice.

About Adarx Pharmaceuticals

Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.

CEO: Dr. Zhen Li, PhD
Employees: 100
Fiscal year end: 12-31
Website: adarx.com

Company profile

Exchange: US
Symbol: ADRX
Market-cap rank: #2823
Listing date: 2026-09-25
Market cap: 1.77B
Float cap: 379.09M
Shares out: 102.20M
Float shares: 21.88M

Sectors & themes

Biotechnology IPOs

Browse all sectors & themes

Quote time 2026-10-08 08:27:44 · For reference only, not investment advice and not tailored to your situation.